- Abivax SA (NASDAQ: ABVX) is scheduled to report earnings on September 21, 2026, with analysts projecting an EPS of -$0.98 and revenue of $799.17 thousand.
- Recent positive interaction with the FDA for its drug candidate, Obefazimod, influenced stock movement, with shares settling at a price of $104.50 after a slight post-announcement dip.
- Analysts maintain optimism with raised price targets, while the company exhibits strong short-term financial health with a current ratio of 7.86, despite a negative price-to-earnings (P/E) ratio of -24.80.
Abivax SA (NASDAQ: ABVX) is a biotechnology company based in Paris, France. The company focuses on developing treatments for inflammatory diseases. Abivax SA is scheduled to report its earnings on September 21, 2026, after the market closes. This event is closely watched by investors for insights into the company's performance and future outlook.
For the upcoming quarter, Wall Street analysts project an earnings per share (EPS) of -$0.98 on revenue of approximately $799.17 thousand. EPS indicates a company's profit per share of stock. A negative EPS means the company had a net loss. Other data, as highlighted by Benzinga Pro, points to a first-half loss of $1.08 per share on revenues of $1.86 million.
Recent news has influenced the stock's movement. On July 30, Abivax SA announced positive interaction with the FDA for its drug candidate, Obefazimod. This news caused shares to rise 2.3%. However, following the earnings date announcement, shares decreased by 0.5% in after-hours trading, settling at a price of $104.50.
Analysts have shown optimism ahead of the earnings call. Piper Sandler's Allison Bratzel increased her price target from $165 to $175, while Truist Securities' Gregory Renza raised his from $135 to $155. Both maintained positive ratings, signaling their belief that the stock's value may increase. Zacks Investment Research also upgraded Abivax SA to a Zacks Rank #2 (Buy).
The company's financial metrics show a mixed picture. Abivax SA has a low debt-to-equity ratio of 0.10, indicating it relies very little on debt. Its current ratio of 7.86 suggests strong short-term financial health. However, a negative price-to-earnings (P/E) ratio of -24.80 confirms the company is not currently profitable.
